Hesham Elghazaly

1.5k total citations
29 papers, 331 citations indexed

About

Hesham Elghazaly is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Hesham Elghazaly has authored 29 papers receiving a total of 331 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cancer Research, 8 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Hesham Elghazaly's work include Liver Disease Diagnosis and Treatment (5 papers), Hepatitis C virus research (4 papers) and MicroRNA in disease regulation (3 papers). Hesham Elghazaly is often cited by papers focused on Liver Disease Diagnosis and Treatment (5 papers), Hepatitis C virus research (4 papers) and MicroRNA in disease regulation (3 papers). Hesham Elghazaly collaborates with scholars based in Egypt, United States and United Kingdom. Hesham Elghazaly's co-authors include Samer S. El‐Kamary, Sahar Sharaf, Fatma El‐Mougy, Ravi Jhaveri, Doa’a A. Saleh, Mohamed Hashem, Yousri Rostom, Marwa Matboli, Sara H. A. Agwa and Sara M. Tolaney and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Infectious Diseases and International Journal of Molecular Sciences.

In The Last Decade

Hesham Elghazaly

26 papers receiving 325 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hesham Elghazaly Egypt 13 89 75 67 62 56 29 331
H. K. Tan Singapore 11 47 0.5× 45 0.6× 29 0.4× 68 1.1× 67 1.2× 24 428
Federica Gonella Italy 8 78 0.9× 42 0.6× 28 0.4× 36 0.6× 68 1.2× 18 301
Cristina B. Geltzeiler United States 10 55 0.6× 83 1.1× 53 0.8× 64 1.0× 174 3.1× 15 503
Long-Bin Jeng Taiwan 13 107 1.2× 65 0.9× 48 0.7× 50 0.8× 70 1.3× 28 385
Carmen González‐Lois Spain 11 42 0.5× 98 1.3× 15 0.2× 41 0.7× 83 1.5× 33 373
Hyun Deok Shin South Korea 9 79 0.9× 84 1.1× 30 0.4× 76 1.2× 92 1.6× 31 324
Lars Karlsen Norway 8 132 1.5× 220 2.9× 20 0.3× 21 0.3× 114 2.0× 19 432
Sang Hyun Hwang South Korea 12 50 0.6× 73 1.0× 39 0.6× 45 0.7× 77 1.4× 36 354
Hidefumi Kishikawa Japan 9 157 1.8× 149 2.0× 10 0.1× 27 0.4× 64 1.1× 39 354
Qingle Zeng China 9 107 1.2× 136 1.8× 19 0.3× 29 0.5× 100 1.8× 35 408

Countries citing papers authored by Hesham Elghazaly

Since Specialization
Citations

This map shows the geographic impact of Hesham Elghazaly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hesham Elghazaly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hesham Elghazaly more than expected).

Fields of papers citing papers by Hesham Elghazaly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hesham Elghazaly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hesham Elghazaly. The network helps show where Hesham Elghazaly may publish in the future.

Co-authorship network of co-authors of Hesham Elghazaly

This figure shows the co-authorship network connecting the top 25 collaborators of Hesham Elghazaly. A scholar is included among the top collaborators of Hesham Elghazaly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hesham Elghazaly. Hesham Elghazaly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sanad, Eman F., et al.. (2024). piR-823 tale as emerging cancer-hallmark molecular marker in different cancer types: a step-toward ncRNA-precision. Naunyn-Schmiedeberg s Archives of Pharmacology. 398(1). 47–68. 13 indexed citations
3.
Sharafeldin, Mohamed, Amany Mostafa, Mohamed H. Alkordi, et al.. (2024). Microfluidic-based fluorescence enhancement of silica-embedded carbon dots for direct detection and quantification of unamplified HCV RNA in clinical samples. Analytica Chimica Acta. 1333. 343396–343396. 1 indexed citations
4.
Wahdan, Sara A., et al.. (2023). Insights into the therapeutic outcomes of trimetazidine/doxorubicin combination in Ehrlich solid-phase carcinoma mouse tumor model. Life Sciences. 328. 121874–121874. 2 indexed citations
5.
Matboli, Marwa, Mahmoud Ali, Mahmoud El‐Meteini, et al.. (2022). Impact of circ-0000221 in the Pathogenesis of Hepatocellular via Modulation of miR-661–PTPN11 mRNA Axis. Pharmaceutics. 14(1). 138–138. 4 indexed citations
6.
7.
Agwa, Sara H. A., et al.. (2022). Identifying SARS-CoV-2 Lineage Mutation Hallmarks and Correlating Them With Clinical Outcomes in Egypt: A Pilot Study. Frontiers in Molecular Biosciences. 9. 817735–817735.
8.
9.
Tolba, Mai F., Hesham Elghazaly, Emira Bousoik, Mohamed M. Elmazar, & Sara M. Tolaney. (2021). Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers. Clinical & Translational Oncology. 23(10). 1979–1994. 18 indexed citations
10.
Agwa, Sara H. A., et al.. (2021). ABHD4-Regulating RNA Panel: Novel Biomarkers in Acute Coronary Syndrome Diagnosis. Cells. 10(6). 1512–1512. 15 indexed citations
11.
Louka, Manal L., et al.. (2018). MicroRNA‐21 as a predictor and prognostic factor for trastuzumab therapy in human epidermal growth factor receptor 2‐positive metastatic breast cancer. Journal of Cellular Biochemistry. 120(3). 3459–3466. 12 indexed citations
12.
Hashem, Mohamed, Ravi Jhaveri, Doa’a A. Saleh, et al.. (2017). Spontaneous Viral Load Decline and Subsequent Clearance of Chronic Hepatitis C Virus in Postpartum Women Correlates With Favorable Interleukin-28B Gene Allele. Clinical Infectious Diseases. 65(6). 999–1005. 25 indexed citations
13.
Elghazaly, Hesham, et al.. (2017). Employing 18 F-FDG PET/CT for distinguishing benign from metastatic adrenal masses. The Egyptian Journal of Radiology and Nuclear Medicine. 48(4). 1065–1071. 2 indexed citations
14.
15.
El‐Kamary, Samer S., Mohamed Hashem, Doa’a A. Saleh, et al.. (2015). Reliability of risk-based screening for hepatitis C virus infection among pregnant women in Egypt. Journal of Infection. 70(5). 512–519. 28 indexed citations
16.
Jhaveri, Ravi, Mohamed Hashem, Samer S. El‐Kamary, et al.. (2015). Hepatitis C Virus (HCV) Vertical Transmission in 12-Month-Old Infants Born to HCV-Infected Women and Assessment of Maternal Risk Factors. Open Forum Infectious Diseases. 2(2). ofv089–ofv089. 27 indexed citations
17.
Rostom, Yousri, et al.. (2013). All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 71(4). 913–919. 19 indexed citations
18.
Elghazaly, Hesham, et al.. (2008). Treatment of Diffuse Pigmented Villonodular Synovitis of the Knee with Combined Surgical and Radiosynovectomy. HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery. 5(1). 19–23. 49 indexed citations
19.
Elghazaly, Hesham, et al.. (2008). Vinorelbine and capecitabine combination as first-line treatment in patients with metastatic breast cancer: Final results of a multicentric trial in Egypt. Journal of Clinical Oncology. 26(15_suppl). 1125–1125. 2 indexed citations
20.
Elghazaly, Hesham, et al.. (2006). Evolution of treatment of high-risk metastatic gestational trophoblastic tumors: Ain Shams University experience. International Journal of Gynecological Cancer. 16(2). 866–874. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. K. Tan Breakdown of academic impact, for papers by Federica Gonella Breakdown of academic impact, for papers by Cristina B. Geltzeiler Breakdown of academic impact, for papers by Long-Bin Jeng Breakdown of academic impact, for papers by Carmen González‐Lois Breakdown of academic impact, for papers by Hyun Deok Shin Breakdown of academic impact, for papers by Lars Karlsen Breakdown of academic impact, for papers by Sang Hyun Hwang Breakdown of academic impact, for papers by Hidefumi Kishikawa Breakdown of academic impact, for papers by Qingle Zeng
Rankless by CCL
2026